Mechanisms involved in the induced differentiation of leukemia cells

被引:137
作者
Tsiftsoglou, AS [1 ]
Pappas, IS [1 ]
Vizirianakis, IS [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Pharmaceut Sci, Pharmacol Lab, GR-54124 Thessaloniki, Greece
关键词
leukemia; differentiation; apoptosis; hematopoietic cells; mechanisms; chemical inducers;
D O I
10.1016/j.pharmthera.2003.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the remarkable progress achieved in the treatment of leukemias over the last several years, many problems (multidrug resistance [MDR], cellular heterogeneity, heterogeneous molecular abnormalities, karyotypic instability, and lack of selective action of antineoplastic agents) still remain. The recent progress in tumor molecular biology has revealed that leukemias are likely to arise from disruption of differentiation of early hematopoietic progenitors that fail to give birth to cell lineage restricted phenotypes. Evidence supporting such mechanisms has been derived from studying bone marrow leukemiogenesis and analyzing differentiation of leukemic cell lines in culture that serve as models of erythroleukemic (murine erythroleukemia [MEL] and human leukemia [K562] cells) and myeloid (human promyelocytic leukemia [HL-60] cells) cell maturation. This paper reviews the current concepts of differentiation, the chemical/pharmacological inducing agents developed thus far, and the mechanisms involved in initiation of leukemic cell differentiation. Emphasis was given on commitment and the cell lineage transcriptional factors as key regulators of terminal differentiation as well as on membrane-mediated events and signaling pathways involved in hematopoietic cell differentiation. The developmental program of MEL cells was presented in considerable depth. It is quite remarkable that the erythrocytic maturation of these cells is orchestrated into specific subprograms and gene expression patterns, suggesting that leukemic cell differentiation represents a highly coordinated set of events that lead to irreversible growth arrest and expression of cell lineage restricted phenotypes. In MEL and other leukemic cells, differentiation appears to be accompanied by differentiation-dependent apoptosis (DDA), an event that can be exploited chemotherapeutically. The mechanisms by which the chemical inducers promote differentiation of leukemic cells have been discussed. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:257 / 290
页数:34
相关论文
共 402 条
[51]   CONSTITUTIVE EXPRESSION OF A C-MYB CDNA BLOCKS FRIEND MURINE ERYTHROLEUKEMIA CELL-DIFFERENTIATION [J].
CLARKE, MF ;
KUKOWSKALATALLO, JF ;
WESTIN, E ;
SMITH, M ;
PROCHOWNIK, EV .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :884-892
[52]   INTERLEUKIN-6 INDUCES MYELOID DIFFERENTIATION OF A HUMAN BIPHENOTYPIC LEUKEMIC-CELL LINE [J].
COHEN, A ;
PETSCHE, D ;
GRUNBERGER, T ;
FREEDMAN, MH .
LEUKEMIA RESEARCH, 1992, 16 (08) :751-760
[53]   RETINOIC ACID-INDUCED GRANULOCYTIC DIFFERENTIATION OF HL-60 MYELOID-LEUKEMIA CELLS IS MEDIATED DIRECTLY THROUGH THE RETINOIC ACID RECEPTOR (RAR-ALPHA) [J].
COLLINS, SJ ;
ROBERTSON, KA ;
MUELLER, L .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (05) :2154-2163
[54]   INDUCTION OF MORPHOLOGICAL AND FUNCTIONAL-DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS (HL-60) BY COMPOUNDS WHICH INDUCE DIFFERENTIATION OF MURINE LEUKEMIA-CELLS [J].
COLLINS, SJ ;
BODNER, A ;
TING, R ;
GALLO, RC .
INTERNATIONAL JOURNAL OF CANCER, 1980, 25 (02) :213-218
[55]   TERMINAL DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS INDUCED BY DIMETHYL-SULFOXIDE AND OTHER POLAR COMPOUNDS [J].
COLLINS, SJ ;
RUSCETTI, FW ;
GALLAGHER, RE ;
GALLO, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (05) :2458-2462
[56]  
CONSTANTINOU A, 1989, CANCER RES, V49, P1110
[57]   CONTINUED WITHDRAWAL FROM THE CELL-CYCLE AND REGULATION OF CELLULAR GENES IN MOUSE ERYTHROLEUKEMIA-CELLS BLOCKED IN DIFFERENTIATION BY THE C-MYC ONCOGENE [J].
COPPOLA, JA ;
PARKER, JM ;
SCHULER, GD ;
COLE, MD .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (04) :1714-1720
[58]  
COPPOLA JA, 1990, ONCOGENE, V5, P1731
[59]  
CORIN RE, 1986, CANCER RES, V46, P1136
[60]  
CREUSOT F, 1982, J BIOL CHEM, V257, P2041